Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

Rhea-AI Summary

Verve Therapeutics announced participation in the Jefferies Gene Therapy/Editing Summit on October 28, 2021, featuring CEO Sekar Kathiresan and CMO Andrew Bellinger. This event will highlight their innovative approach to cardiovascular disease through single-course gene editing medicines. The company's lead candidate, VERVE-101, aims to permanently disable the PCSK9 gene, significantly reducing low-density lipoprotein cholesterol (LDL-C) levels. A live webcast will be accessible on their website, archived for 60 days.

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 9:00 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.vervetx.com. The webcast will be archived for 60 days following the presentation.

About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

Media Contact
Gina Nugent, 617-460-3579
Ten Bridge Communications
gina@tenbridgecommunications.com

Investor Contact
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

FAQ

What is Verve Therapeutics' lead product candidate, VERVE-101?

VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver to lower LDL-C levels, reducing cardiovascular disease risk.

When is Verve Therapeutics participating in the Jefferies Gene Therapy/Editing Summit?

Verve Therapeutics will participate in the summit on October 28, 2021, at 9:00 a.m. ET.

How can I watch the presentation by Verve Therapeutics?

The presentation will be available via live webcast on Verve's investor website, and it will be archived for 60 days.

What cardiovascular disease targets is Verve Therapeutics focusing on?

Verve Therapeutics is targeting PCSK9 and ANGPTL3 genes to lower blood lipid levels, particularly LDL-C.

What disease is VERVE-101 initially being developed to treat?

VERVE-101 is being developed for patients with heterozygous familial hypercholesterolemia.